OL
TGTX icon

Odyssean LLC’s TG Therapeutics TGTX Stock Holding History

Odyssean LLC’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Buy
31,652
+16,398
+107% +$671K 0.28% 137
2026
Q1 		$507K Sell
15,254
-511
-3% -$15.2K 0.19% 196
2025
Q4 		$470K Buy
+15,765
New +$515K 0.34% 163

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Odyssean LLC's TGTX Position: Q2 2026 in Review

Odyssean LLC increased its TG Therapeutics (TGTX) stake by 107% in Q2 2026, buying an estimated $671K and bringing the position to 31,652 shares worth $1.74M. The position accounts for 0.28% of the portfolio, ranked #137.

Odyssean LLC first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Odyssean LLC held 31,652 shares of TG Therapeutics worth $1.74M as of Q2 2026.
  • Odyssean LLC bought 16,398 TG Therapeutics shares in Q2 2026, an estimated $671K.
  • TG Therapeutics made up 0.28% of Odyssean LLC's portfolio in Q2 2026, its #137 holding.
  • Odyssean LLC first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Odyssean LLC's 13F filing for Q2 2026, filed 14 Aug 2026.